VolitionRx (VNRX) Presents At Inaugural Global Conference - Slideshow

Company Overview - Volition is a diagnostic company focused on epigenetic markers for human and veterinary use, targeting a total addressable market (TAM) of $70 billion[4, 50] - The company's Nu.Q® tests are simple, low-cost blood tests adaptable to various diagnostic workflows, supported by 96 granted and 120 pending patents[5] Veterinary Cancer Diagnostics - The Nu.Q® Vet Cancer Test targets an $11 billion TAM for canine and feline cancer screening and monitoring[10] - In the U.S., approximately 6 million dogs are diagnosed with cancer annually, and nearly 50% of dogs over 10 will develop cancer[9] - The Nu.Q® Vet Cancer Test has a specificity of 97% in detecting cancer in dogs, with detection rates of 82% for Hemangiosarcoma, 77% for Lymphoma, and 76% for Systemic Cancers[11] Sepsis Diagnostics - The Nu.Q® NETs assay is being developed for early detection and risk stratification of sepsis, a condition with an estimated economic burden of $62 billion annually in the U.S[27] - The annual total addressable market for Nu.Q® NETs in sepsis risk stratification and monitoring is estimated to be over $22 billion, with $14.8 billion for screening on admission to hospitals and $7.3 billion for monitoring disease in the Intensive Treatment Unit (ITU)[43] Commercial Strategy and Financials - Volition has signed a global supply agreement with IDEXX Laboratories Inc and an agreement of up to $28 million with Heska[45] - As of May 9, 2023, Volition's market capitalization was $123.1 million, with cash-on-hand of approximately $10 million as of March 31, 2023[51]